{
  "docId": "019de076-906b-74a9-92f8-5c2872231d60",
  "docSlug": "a8776e7183e96a109d1a49143fc2ff88",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 26 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 26,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "traction",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 42,
  "notes": "Data presented at EASL 2022, AASLD 2022, GHS 2023.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-906b-74a9-92f8-5c2872231d60/11",
  "deckHref": "/decks/019de076-906b-74a9-92f8-5c2872231d60",
  "deckJsonHref": "/decks/019de076-906b-74a9-92f8-5c2872231d60.json",
  "deckAnchorHref": "/decks/019de076-906b-74a9-92f8-5c2872231d60#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.05,
        "y": 0.135
      },
      "kind": "chart",
      "text": "Mean HBsAg log10 change from baseline",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c38aebf-513c-4c63-95a2-e9173d2c9478",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.78
      },
      "kind": "list",
      "text": "All Cohorts achieved at least a -1.8 log10 decline in mean HBsAg at the end of the treatment period (Week 48)\nThere were no significant differences in mean HBsAg declines between the 60 mg and 90 mg doses or between different dosing intervals\nMean HBsAg levels remained below baseline values at Week 48 Follow Up\nAB-729 was well-tolerated at all dose levels and intervals, with no discontinuations due to AEs or treatment-related Grade 3 or 4 AEs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef9076ba-e3bb-4179-93e4-0d6556e8bfb1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.48,
        "x": 0.48,
        "y": 0.135
      },
      "kind": "table",
      "text": "Mean HBsAg log10 IU/mL change from baseline at key timepoints",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1e2c1bca-e884-42a2-9f65-4d1c0593b411",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "AB-729-001: Comparable mean HBsAg declines were observed in all Cohorts",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "98c04bbe-a6ec-4e39-9fb8-7128eac808ec",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "aa277a88-7563-4f49-8854-e05c350ed9db",
      "evidence": "table/data: Mean HBsAg log10 IU/mL change from baseline at key timepoints",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 26,
      "from": 8,
      "beatId": "b0891741-a256-4e4e-a8d2-65a9f9895b7f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents Arbutus Biopharma's pipeline and clinical trial results as a solution.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    },
    {
      "to": 18,
      "from": 11,
      "beatId": "bb704643-20a7-459a-9df1-5b5cea9225d9",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document presents clinical trial results and data.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 18,
      "from": 11,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "9268b1b4-494b-44ee-8454-6a997fc0aa8b",
      "evidence": "The document presents clinical trial results and data.",
      "position": 1,
      "objective": "Can Imdusiran RNAi therapeutic and AB-101 oral PD-L1 inhibitor provide a quick win or a big bet for investors?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}